4/26/2022 8:49:47 AM
Evaxion To Utilize Personalis' ImmunoID Platform To Evaluate Efficacy Of Combination Therapy For Late-Stage Melanoma
4/11/2022 9:06:11 AM
Personalis And Merck KGaA, Darmstadt, Germany To Present Comprehensive Tumor Subtyping Collaboration Data
11/4/2021 7:14:05 AM
Personalis Q3 Net Loss $17.7 Mln Vs. Net Loss $9.5 Mln Last Year
1/26/2021 10:51:03 PM
Personalis Prices Public Offering Of 3.95 Mln Shares At $38/Shr